MGX

insider transactions

Metagenomi Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-10.8K

0 buy · 10.8K sell

Net value · 365d

-$15.2K

$0 in · $15.2K out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 10.8K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 9, 26

Laurence Reid

Director

$0

17.4K sh

Own New
Grant·A
Jun 9, 26

Juergen Eckhardt

Director

$0

21.0K sh

Own New
Grant·A
Jun 9, 26

Willard H Dere

Director

$0

21.0K sh

Own New
Sell·S
Jun 5, 26

Pamela Wapnick KEY

Chief Financial Officer

$3.7K

2.9K sh · $1.30

Own -1%
Sell·S
Jun 5, 26

Matthew Wein

Title: General Counsel, Compl…

$725

558 sh · $1.30

Own -0%
Sell·S
Jun 5, 26

Jian Irish KEY

President and Chief Executive…

$4.9K

3.7K sh · $1.30

Own -1%
Grant·A
Apr 1, 26

Matthew Wein

Title: General Counsel, Compl…

$0

68.0K sh

Own New
Grant·A
Apr 1, 26

Matthew Wein

Title: General Counsel, Compl…

$0

11.0K sh

Own +10%
Grant·A
Apr 1, 26

Pamela Wapnick KEY

Chief Financial Officer

$0

144.0K sh

Own New
Grant·A
Apr 1, 26

Pamela Wapnick KEY

Chief Financial Officer

$0

24.0K sh

Own +13%
Grant·A
Apr 1, 26

Jian Irish KEY

Title: President and Chief Ex…

$0

276.0K sh

Own New
Grant·A
Apr 1, 26

Jian Irish KEY

Title: President and Chief Ex…

$0

46.0K sh

Own +14%
Sell·S
Mar 5, 26

Pamela Wapnick KEY

Chief Financial Officer

$2.5K

1.6K sh · $1.60

Own -1%
Sell·S
Mar 5, 26

Matthew Wein

Title: General Counsel, Compl…

$771

482 sh · $1.60

Own -0%
Sell·S
Mar 5, 26

Jian Irish KEY

Chief Executive Officer

$2.6K

1.6K sh · $1.60

Own -0%
Other·D
Jan 6, 26

Willard H Dere

Director

—

2.2K sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

734 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

1.8K sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

513 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

1.0K sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

125 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

368 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

450 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

1.0K sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

544 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

800 sh

Own -100%
Other·D
Jan 6, 26

Willard H Dere

Director

—

2.5K sh

Own -100%
Other·U
Jan 6, 26

Willard H Dere

Director

—

1.6K sh
Other·G
Dec 5, 25

Jian Irish KEY

Chief Executive Officer

$0

228.5K sh

Own -41%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 9, 2026	Laurence Reid	Director	Grant A	17.4K	New	—	$0
Jun 9, 2026	Juergen Eckhardt	Director	Grant A	21.0K	New	—	$0
Jun 9, 2026	Willard H Dere	Director	Grant A	21.0K	New	—	$0
Jun 5, 2026	Pamela Wapnick KEY	Chief Financial Officer	Sell S	2.9K	-1%	$1.30	$3.7K
Jun 5, 2026	Matthew Wein	Title: General Counsel, Compliance Officer and Corporate Secretary	Sell S	558	-0%	$1.30	$725
Jun 5, 2026	Jian Irish KEY	President and Chief Executive Officer	Sell S	3.7K	-1%	$1.30	$4.9K
Apr 1, 2026	Matthew Wein	Title: General Counsel, Compliance Officer and Corporate Secretary	Grant A	68.0K	New	—	$0
Apr 1, 2026	Matthew Wein	Title: General Counsel, Compliance Officer and Corporate Secretary	Grant A	11.0K	+10%	—	$0
Apr 1, 2026	Pamela Wapnick KEY	Chief Financial Officer	Grant A	144.0K	New	—	$0
Apr 1, 2026	Pamela Wapnick KEY	Chief Financial Officer	Grant A	24.0K	+13%	—	$0
Apr 1, 2026	Jian Irish KEY	Title: President and Chief Executive Officer	Grant A	276.0K	New	—	$0
Apr 1, 2026	Jian Irish KEY	Title: President and Chief Executive Officer	Grant A	46.0K	+14%	—	$0
Mar 5, 2026	Pamela Wapnick KEY	Chief Financial Officer	Sell S	1.6K	-1%	$1.60	$2.5K
Mar 5, 2026	Matthew Wein	Title: General Counsel, Compliance Officer and Corporate Secretary	Sell S	482	-0%	$1.60	$771
Mar 5, 2026	Jian Irish KEY	Chief Executive Officer	Sell S	1.6K	-0%	$1.60	$2.6K
Jan 6, 2026	Willard H Dere	Director	Other D	2.2K	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	734	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	1.8K	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	513	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	1.0K	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	125	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	368	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	450	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	1.0K	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	544	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	800	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other D	2.5K	-100%	—	—
Jan 6, 2026	Willard H Dere	Director	Other U	1.6K	—	—	—
Dec 5, 2025	Jian Irish KEY	Chief Executive Officer	Other G	228.5K	-41%	—	$0

About MGX insider trading

This page tracks insider transactions for Metagenomi Therapeutics, Inc. (MGX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.